What alternative hormone replacement therapy regimens can be used for a patient who needs a combined estrogen‑progestin transdermal patch (Combipatch) but whose insurance does not cover it?

Alternative HRT Regimens to Combipatch

If combined estrogen-progestin transdermal patches are unavailable, use transdermal 17β-estradiol patches (50 μg daily) continuously with oral micronized progesterone (200 mg daily for 12-14 days every 28 days) as your first alternative. 1

Primary Alternative: Separate Transdermal Estradiol + Oral Progestin

When combined patches like Combipatch are not covered, the most practical approach is to prescribe the components separately:

Estradiol Component

• Transdermal 17β-estradiol patches: 50-100 μg daily (changed twice weekly or weekly depending on brand) 1
• Apply continuously throughout the 28-day cycle 1
• Transdermal administration avoids first-pass hepatic metabolism, reducing risks of venous thromboembolism, stroke, and gallbladder disease compared to oral estrogen 1, 2

Progestin Component (for endometrial protection)

First choice: Micronized progesterone (MP)

• 200 mg orally or vaginally for 12-14 days every 28 days (sequential regimen) 1
• MP is associated with lower cardiovascular disease and venous thromboembolism risk compared to synthetic progestins 1, 2
• Provides adequate endometrial protection when given cyclically 1

Second choice alternatives if MP unavailable:

• Medroxyprogesterone acetate (MPA): 10 mg daily for 12-14 days per month 1
• Dydrogesterone: 10 mg daily for 12-14 days per month 1

Secondary Alternative: Oral Combined Tablets

If transdermal administration is contraindicated or refused:

Oral 17β-estradiol 1-2 mg + progestin combinations 1

• Examples: 17β-estradiol + dydrogesterone (5 mg) or 17β-estradiol + dienogest (2 mg) 1
• Available in both sequential and continuous combined formulations 1
• Less preferred than transdermal due to increased thrombotic and hepatic risks 1, 2

Continuous Combined Regimen Option (for amenorrhea)

If the patient prefers to avoid withdrawal bleeding:

Continuous regimen requires daily progestin:

• Transdermal estradiol 50 μg daily PLUS one of: 1
  • Oral norethisterone: minimum 1 mg daily 1
  • Oral MPA: 2.5 mg daily 1
  • Oral dydrogesterone: 5 mg daily 1

This approach typically results in amenorrhea after 6-12 months, though irregular bleeding is common initially 3

Important Considerations

Endometrial Protection

• Sequential progestin for at least 12-14 days per cycle is mandatory for women with an intact uterus to prevent endometrial hyperplasia 1, 3
• Continuous combined regimens provide superior long-term endometrial protection compared to sequential regimens 2

Cost-Effectiveness

• Separate components (generic estradiol patches + oral micronized progesterone) are typically more affordable than branded combination products 4
• Generic transdermal estradiol patches are widely available 5

Monitoring

• Perform endometrial assessment if unscheduled bleeding persists beyond 6 months 3
• Re-evaluate need for continued therapy at 3-6 month intervals 3

Common Pitfalls to Avoid

• Do not use estrogen-only therapy in women with an intact uterus - this significantly increases endometrial cancer risk 3
• Avoid progestins with anti-androgenic effects (cyproterone, drospirenone) if the patient has concerns about libido 1
• Do not prescribe ethinyl estradiol-based contraceptives as HRT - these have higher thrombotic risk than 17β-estradiol formulations 1, 2